Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company based in Tarrytown, New York, specializing in the development of innovative medicines for serious diseases. Its competitive position is bolstered by a robust pipeline, including flagship products like EYLEA for eye diseases and Dupixent for allergic conditions, which contribute significantly to its revenue.
Regeneron generates revenue primarily through the sale of its proprietary drugs, leveraging strong pricing power due to the high unmet medical needs in its therapeutic areas. Its competitive advantages include a strong R&D pipeline, strategic partnerships, and a history of successful drug development.
FDA approval of new drugs or indications, particularly in its pipeline like the potential expansion of Dupixent
Sales growth of EYLEA and Dupixent, which are critical to revenue stability
Partnership announcements or collaborations that enhance its pipeline
Market share changes in key therapeutic areas
Regulatory changes that could impact drug approval processes or pricing
Technological disruption in drug development or delivery methods
Emergence of biosimilars for EYLEA and Dupixent
Increased competition from other biotech firms with similar product offerings
Low debt levels mitigate financial risk, but reliance on a few key products poses revenue concentration risk
moderate - While Regeneron operates in a relatively recession-resistant sector, economic downturns can impact healthcare spending and insurance coverage.
Regeneron has minimal direct exposure to interest rates; however, higher rates could affect the overall investment climate and valuations in the biotech sector.
minimal - The company has a low debt-to-equity ratio of 0.09, indicating strong financial health and limited reliance on credit.
growth - Investors are drawn to Regeneron for its strong pipeline and potential for significant revenue growth from new drug approvals.
moderate - The stock has shown some volatility, with a 1-year return of 18.4%, reflecting market reactions to pipeline developments and earnings results.